The definition for sepsis from the third international consensus states that “sepsis is a lethal organ function disorder induced by an aberrant reaction to infections.”1 Myocardial tissue is the most common target during the progression of sepsis, and myocardial tissue damage is also the starting point for multiple organ dysfunction syndrome in sepsis17. Gram-negative bacterial endotoxin (LPS) is a key mediator of sepsis-associated multiple organ dysfunction or mortality18. Therefore, endotoxemia is often used to simulate the acute inflammatory response associated with early sepsis19. Several experimental studies have established animal and cell models of sepsis using LPS-induced excessive inflammation and organ impairment20–22. Macrophages and cardiomyocytes are the main effector cells in septic myocardial injury. After LPS induction, both macrophages and cardiomyocytes can release substantial amounts of inflammatory mediators23.
Myocardial infiltration of immune cells is a recognized feature of severe sepsis, and the main cell types involved are monocytes/macrophages24. Cytokines, especially IL-1β, IL-6, and TNF-α, are major contributors to septic myocardial injury25. When LPS binds to its receptor expressed on macrophages, a cascade of inflammatory responses is triggered26. In this study, we found that ginsenoside Rd can significantly reduce the LPS-induced release of inflammatory factors in RAW264.7 cells, including TNF-α, IL-6, and IL-1β, in a concentration-dependent manner. These results suggest that ginsenoside Rd exerts a significant inhibitory effect on the release of inflammatory factors from macrophages in sepsis, thereby preventing myocardial and organ damage.
Numerous clinical and animal studies have confirmed the presence of myocardial cell suppression in sepsis27,28. The myocardium not only experiences inflammatory infiltration by immune cells but also produces an inflammatory response when induced by LPS, leading to myocardial cell apoptosis, calcium homeostasis imbalance29, energy metabolism disorders30, increased oxidative stress levels, and excessive NO production31. All these factors contribute to decreased cardiac contractility, diastolic dysfunction, reduced ejection fraction, and a lower cardiac index, which ultimately lead to myocardial injury32. In this study, we found that ginsenoside Rd can improve the survival rate of cardiomyocytes, possibly by reducing myocardial cell apoptosis. Excessive LDH production is a hallmark indicator of myocardial injury, and increased intracellular Ca2+ levels also disrupt calcium homeostasis and lead to myocardial injury33. The findings of the present study indicated that ginsenoside Rd can reduce LDH and Ca2+ levels in cardiomyocytes, thereby alleviating LPS-induced myocardial injury. ROS production reflects the overall oxidative stress level of cells, and MDA content can indirectly reflect the degree of oxidative stress in the body or tissue cells34. We herein observed that ginsenoside Rd could reduce ROS and MDA levels in cardiomyocytes. In addition, NO influences several aspects of the inflammatory cascade, and excessive NO production can induce cardiomyocyte death35. We also found that ginsenoside Rd could reduce NO levels in cardiomyocytes. These results suggest that ginsenoside Rd can reduce the extent of LPS-induced myocardial cell damage, as evidenced by increased cell survival rates, reduced cell apoptosis, lower myocardial injury marker levels, and suppressed oxidative stress and inflammatory responses.
The MAPK and NF-κB signaling pathways play crucial roles in septic myocardial injury36. These pathways are important in regulating inflammation, cell survival, apoptosis, and stress responses. The MAPK family mainly includes three key signaling proteins: ERK, JNK, and p38. ERK is mainly related to cell proliferation and differentiation37. JNK and p38, known as stress-related protein kinases, are mainly involved in cellular inflammation, oxidative stress responses, and apoptosis38. The classical NF-κB pathway involves a heterodimer composed of p65 and p50 that activates the expression of genes related to inflammatory responses through nuclear translocation39. Mechanistically, there is an intersection between the MAPK and NF-κB signaling pathways. It is currently believed that the p38 MAPK signaling pathway is a major upstream factor that activates NF-κB40. Upon activation, p38 MAPK can phosphorylate IκB, leading to its degradation and the release of the p50/p65 NF-κB heterodimer, directly triggering NF-κB pathway activation and nuclear translocation and driving the transcription of NF-κB target genes in the nucleus. These alterations promote the expression of the inflammatory factors TNF-α, IL-6, and IL-1β, thereby activating inducible nitric oxide synthase to promote NO expression41. Previous studies have reported that ginsenoside Rd can inhibit the NF-κB signaling pathway42. In the present study, we observed that LPS activated the MAPK and NF-κB signaling pathways in both macrophages and cardiomyocytes. In macrophages, ginsenoside Rd inhibited the phosphorylation of ERK, JNK, and p38 and suppressed the phosphorylation and nuclear translocation of p65. Similarly, in cardiomyocytes, ginsenoside Rd inhibited the phosphorylation of JNK, p38, and p65. These results indicate that ginsenoside Rd can inhibit the MAPK and NF-κB signaling pathways in both cardiomyocytes and macrophages, thereby preventing LPS-induced septic myocardial injury.
In summary, our study confirmed that ginsenoside Rd can reduce the inflammatory response of macrophages by inhibiting the MAPK and NF-κB signaling pathways, improve cardiomyocyte survival, reduce cardiomyocyte apoptosis, and inhibit myocardial oxidative stress and inflammatory responses (Fig. 7). Furthermore, our study demonstrated that ginsenoside Rd has the potential to be used in the treatment of septic myocardial injury. Further animal experiments are warranted to further confirm this conclusion.